Eli Lilly has announced to buy a biopharmaceutical company, Dermira, for a whopping sum of USD 1.1 Billion in an all-cash transaction.
Through the acquisition, Eli Lilly is planning to expand its immunology pipeline by adding lebrikizumab, which is a novel, investigational, monoclonal antibody. The drug is designed to bind IL-13 with high affinity and is under Phase 3 clinical development trial for the treatment of moderate-to-severe atopic dermatitis in adolescent and adult patients, ages 12 years and older. The USFDA had already given the drug Fast Track designation last month.
So far, the only approved therapy that targets the IL-4/13 pathway is Dupilumab, a...
